JP2000507544A - 痛みの治療方法 - Google Patents
痛みの治療方法Info
- Publication number
- JP2000507544A JP2000507544A JP9534520A JP53452097A JP2000507544A JP 2000507544 A JP2000507544 A JP 2000507544A JP 9534520 A JP9534520 A JP 9534520A JP 53452097 A JP53452097 A JP 53452097A JP 2000507544 A JP2000507544 A JP 2000507544A
- Authority
- JP
- Japan
- Prior art keywords
- pain
- atypical
- composition
- atypical antipsychotic
- antipsychotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.痛みを治療するための組成物であって、鎮痛用量の、リスペリドン、クロ ザピン、セロクエル、セルチンドール、ジプラシドン、およびゾテピンからなる 群から選ばれる非定型的抗精神病薬またはその医薬的に許容される塩または溶媒 和物と1またはそれ以上の痛みの治療に用いる別の薬剤を、非定型的抗精神病薬 と痛みの治療に用いる別の薬剤との重量比、非定型的抗精神病薬約1に対し痛み の治療に用いる別の薬剤約1〜約1000で含む組成物。 2.痛みの治療に用いる別の薬剤がアスピリン、イブプロフェン、アセトアミ ノフェン、インドメタシン、チレノール#3、三環状抗鬱薬(例えば、デシプラ ミン、イミプラミン、アミトリプチリン、ノルトリプチル)、抗痙攣薬(例えば 、カルバマゼピン、バルプロエート)、およびセロトニン再吸収阻害剤(例えば 、フルオキセチン、パラオキセチン、セルトラリン)、複合セロトニン−ノルエ ピネフリン再吸収阻害剤(例えば、ベンラファキシン、デュロキセチン)、セロ トニンレセプターアゴニストおよびアンタゴニスト、コリン作動性(ムスカリン 性およびニコチン性)鎮痛薬、アドレナリン作動性物質、およびニューロキニン アンタゴニストからなる群から選ばれる請求項1に記載の組成物。 3.非定型的抗精神病薬がリスペリドンである請求項1に記載の組成物。 4.痛みの治療に用いる別の薬剤がアセトアミノフェン、コリン作動性鎮痛薬 、およびニューロキニンアンタゴニストからなる群から選ばれる請求項2に記載 の組成物。 5.非定型的抗精神病薬と痛みの治療に用いる別の薬剤との重量比が非定型的 抗精神病薬約1に対し痛みの治療に用いる別の薬剤約1〜約100である請求項 1に記載の組成物。 6.痛みの治療に用いる別の薬剤がアセトアミノフェン、メペリジン、塩酸ア ルファプロジン、フェンタニル、トラマドール、ケトロラック、アロプリノール 、マレイン酸メチセルジド、メトトリメプラジン、およびインドメタシンからな る群から選ばれる請求項5に記載の組成物。 7.非定型的抗精神病薬と痛みの治療に用いる別の薬剤との重量比が非定型的 抗精神病薬約1に対して痛みの治療に用いる薬剤約1〜約10である請求項5に 記載の組成物。 8.非定型的抗精神病薬と痛みの治療に用いる別の薬剤との重量比が非定型的 抗精神病薬約1に対して痛みの治療に用いる別の薬剤約1〜約3である請求項7 に記載の組成物。 9.痛みの治療に用いる別の薬剤がアセトアミノフェンである請求項8に記載 の組成物。 10.非定型的抗精神病薬がクロザピンである請求項1に記載の組成物。 11.非定型的抗精神病薬がセロクエルである請求項1に記載の組成物。 12.非定型的抗精神病薬がセルチンドールである請求項1に記載の組成物。 13.非定型的抗精神病薬がジプラシドンである請求項1に記載の組成物。 14.非定型的抗精神病薬がゾテピンである請求項1に記載の組成物。 15.痛みを治療する方法であって、リスペリドン、クロザピン、セロクエル 、セルチンドール、ジプラシドン、およびゾテピンからなる群から選ばれる非定 型的抗精神病薬またはその医薬的に許容される塩もしくは溶媒和物と1またはそ れ以上の痛みの治療に用いる薬剤を、非定型的抗精神病薬と痛みを治療するのに 用いる薬剤の重量比、非定型的抗精神病薬約1に対し痛みの治療に用いる薬剤約 1〜約1000で含む、鎮痛用量の組成物を投与することを含む方法。 16.痛みの治療に用いる薬剤がアセトアミノフェン、インドメタシン、チレ ノール#3、三環状抗鬱薬(例えば、デシプラミン、イミプラミン、アミトリプ チリン、ノルトリプチル)、抗痙攣薬(例えば、カルバマゼピン、バルプロエー ト)、およびセロトニン再吸収阻害剤(例えば、フルオキセチン、パラオキセチ ン、セルトラリン)、複合セロトニン−ノルエピネフリン再吸収阻害剤(例えば 、ベンラファキシン、デュロキセチン)、セロトニンレセプターアゴニストおよ びアンタゴニスト、コリン作動性(ムスカリン性およびニコチン性)鎮痛薬、ア ドレナリン作動性物質、およびニューロキニンアンタゴニストからなる群から選 ばれる請求項15に記載の方法。 17.痛みの治療に用いる薬剤がアセトアミノフェン、メペリジン、塩酸アル ファプロジン、フェンタニル、トラマドール、ケトロラック、アロプリノール、 マレイン酸メチセルジド、メトトリメプラジン、およびインドメタシンからなる 群から選ばれる請求項16に記載の方法。 18.哺乳動物の痛みを治療する方法であって、そのような治療を必要とする 哺乳動物に対し、鎮痛用量の、リスペリドン、クロザピン、セロクエル、セルチ ンドール、ジプラシドン、およびゾテピンからなる群から選ばれる非定型的抗精 神病薬またはその医薬的に許容される塩もしくは溶媒和物を投与することを含む 方法。 19.非定型的抗精神病薬がクロザピンである請求項18に記載の方法。 20.非定型的抗精神病薬がリスペリドンである請求項18に記載の方法。 21.非定型的抗精神病薬がセロキエルである請求項18に記載の方法。 22.非定型的抗精神病薬がセルチンドールである請求項18に記載の方法。 23.非定型的抗精神病薬がジプラシドンである請求項18に記載の方法。 24.非定型的抗精神病薬がゾテピンである請求項18に記載の方法。 25.痛みがニューロパシー痛である請求項18に記載の方法。 26.痛みが侵害受容痛である請求項18に記載の方法。 27.痛みの治療に用いるための、リスペリドン、クロザピン、セロクエル、 セルチンドール、ジプラシドン、およびゾテピンからなる群から選ばれる非定型 的抗精神病薬またはその医薬的に許容される塩もしくは溶媒和物。 28.鎮痛に用いるための、リスペリドン、クロザピン、セロクエル、セルチ ンドール、ジプラシドン、およびゾテピンからなる群から選ばれる非定型的抗精 神病薬またはその医薬的に許容される塩もしくは溶媒和物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1415296P | 1996-03-25 | 1996-03-25 | |
US60/014,152 | 1996-03-25 | ||
PCT/US1997/004699 WO1997035584A1 (en) | 1996-03-25 | 1997-03-24 | Method for treating pain |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000507544A true JP2000507544A (ja) | 2000-06-20 |
JP2000507544A5 JP2000507544A5 (ja) | 2004-12-02 |
Family
ID=21763836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9534520A Ceased JP2000507544A (ja) | 1996-03-25 | 1997-03-24 | 痛みの治療方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US6444665B1 (ja) |
EP (1) | EP0906104A4 (ja) |
JP (1) | JP2000507544A (ja) |
AU (1) | AU2587297A (ja) |
CA (1) | CA2250042A1 (ja) |
WO (1) | WO1997035584A1 (ja) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997035584A1 (en) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Method for treating pain |
ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
ES2151828B1 (es) | 1998-07-10 | 2001-08-16 | Esteve Labor Dr | Empleo de derivados de tetrahidropiridinas (ohidroxi-piperidinas)-b utilazoles en la elaboracion de un medicamento para el tratamiento del dolor. |
JP2002529499A (ja) * | 1998-11-13 | 2002-09-10 | イーライ・リリー・アンド・カンパニー | 痛みの治療方法 |
US6280763B1 (en) | 1999-05-10 | 2001-08-28 | Pierce Management, Llc | Apparatus and method for transdermal delivery of bupropion |
DE19924929C2 (de) * | 1999-05-31 | 2001-05-31 | Elegene Gmbh | Neues Verfahren zur Untersuchung der Eignung eines Materials als Pharmakon |
DE60035232T2 (de) | 1999-07-01 | 2008-02-14 | Pharmacia & Upjohn Co. Llc, Kalamazoo | (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom |
US20060083691A1 (en) * | 2000-05-10 | 2006-04-20 | Wermeling Daniel P | Intranasal opioid compositions, delivery devices and methods of using same |
US20040115133A1 (en) * | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
US6630462B2 (en) | 2000-11-17 | 2003-10-07 | Adolor Corporation | Delta agonist analgesics |
DE10112798A1 (de) * | 2001-03-16 | 2002-10-02 | Elegene Gmbh | Vorrichtung und Verfahren zur automatischen Erzeugung einer Wärmevermeidungsreaktion von Nematoden oder ähnlichen Lebewesen |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
SE0102855D0 (sv) * | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | Method of treatment |
EP1434576A4 (en) | 2001-09-13 | 2006-03-29 | Kenneth E Miller | METHOD FOR RELIEVING PAIN |
US6635675B2 (en) * | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
WO2003066039A1 (en) * | 2002-02-08 | 2003-08-14 | Abbott Laboratories | Combination therapy for treatment of schizophrenia |
US20050096395A1 (en) * | 2002-02-12 | 2005-05-05 | Rao Srinivas G. | Methods of treating attention deficit/hyperactivity disorder (adhd) |
MXPA04009385A (es) * | 2002-03-26 | 2005-01-25 | Teva Pharma | Microparticulas de drogas. |
EP1499309A4 (en) * | 2002-04-24 | 2008-05-28 | Cypress Bioscience Inc | PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES |
WO2003101492A2 (en) * | 2002-05-30 | 2003-12-11 | Neurosearch A/S | Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain |
US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
WO2004030633A2 (en) * | 2002-10-03 | 2004-04-15 | Cypress Bioscience, Inc. | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders |
CN1726037B (zh) * | 2002-11-26 | 2010-05-05 | 艾利斯达医药品公司 | 抗精神病药用于制备通过吸入传送治疗头痛的药物中的应用 |
PT1567164E (pt) | 2002-11-26 | 2009-03-31 | Alexza Pharmaceuticals Inc | Utilização de loxapina para o fabrico de um medicamento para o tratamento da dor |
AR042806A1 (es) | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
CA2511619C (en) | 2002-12-27 | 2011-07-12 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
US20040234916A1 (en) | 2003-05-21 | 2004-11-25 | Alexza Molecular Delivery Corporation | Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
WO2004105690A2 (en) * | 2003-05-23 | 2004-12-09 | Cypress Bioscience, Inc. | Treatment of chronic pain associated with drug or radiation therapy |
MXPA05012538A (es) * | 2003-05-23 | 2006-02-22 | Otsuka Pharma Co Ltd | Derivados de carbostirilo y estabilizantes del estado de animo para trastornos del mismo. |
NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
CA2580730C (en) * | 2003-09-25 | 2015-01-13 | Cenomed, Inc. | Tetrahydroindolone derivatives for treatment of neurological conditions |
US20050107439A1 (en) * | 2003-11-10 | 2005-05-19 | Helton David R. | Composition and method for treating emesis |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
WO2006127184A1 (en) | 2005-05-20 | 2006-11-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
UA97349C2 (uk) * | 2005-09-08 | 2012-02-10 | Х. Луннбэк А/С | Стійкі тверді склади сертиндолу |
US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
EP1795609A1 (en) | 2005-12-06 | 2007-06-13 | Sanofi-Aventis Deutschland GmbH | Method for the diagnosis and treatment of cardiovascular diseases |
WO2007067714A2 (en) * | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
AR058389A1 (es) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
AU2007253814A1 (en) | 2006-05-19 | 2007-11-29 | Janssen Pharmaceutica N.V. | Co-therapy for the treatment of epilepsy |
US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
WO2008128166A1 (en) * | 2007-04-13 | 2008-10-23 | Concert Pharmaceuticals Inc. | Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds |
WO2009062134A1 (en) * | 2007-11-09 | 2009-05-14 | Cenomed Biosciences, Llc | Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds |
US20090264443A1 (en) * | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
AU2009271362B2 (en) | 2008-06-23 | 2014-03-13 | Janssen Pharmaceutica Nv | Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
US8697735B2 (en) | 2008-07-25 | 2014-04-15 | Bionevia Pharmaceuticals, Inc. | Solid forms of epalrestat |
EA023435B1 (ru) | 2008-09-06 | 2016-06-30 | Бионевия Фармасьютикалс, Инк. | Фармацевтическая композиция, включающая новый холиновый сокристалл эпалрестата |
KR20150036333A (ko) | 2012-07-02 | 2015-04-07 | 피엔비 베스퍼 라이프 사이언스 피브이티 리미티드 | 신규한 콜레시스토키닌 수용체 리간드 |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
PL3639828T3 (pl) | 2013-12-24 | 2022-05-02 | Virginia Commonwealth University | Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby |
US20190117637A1 (en) * | 2016-06-13 | 2019-04-25 | Board Of Regents Of The University Of Texas System | Pharmaceutical compositions and methods for treatment of pain |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
WO2020212948A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
GB1247067A (en) * | 1968-02-16 | 1971-09-22 | Fujisawa Pharmaceutical Co | Tricyclic enol ether compounds and the preparation thereof |
US3704345A (en) * | 1971-03-19 | 1972-11-28 | Bell Telephone Labor Inc | Conversion of printed text into synthetic speech |
DE2918778A1 (de) * | 1979-05-10 | 1980-11-20 | Basf Ag | 6-substituierte 11-alkylen-morphantridine |
GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
GB8908085D0 (en) * | 1989-04-11 | 1989-05-24 | Lundbeck & Co As H | New therapeutic use |
US5238945A (en) | 1989-04-11 | 1993-08-24 | H. Lundbeck A/S | Method of treating psychoses |
US5045539A (en) * | 1989-07-10 | 1991-09-03 | Hoechst-Roussel Pharmaceuticals Inc. | 1H-indolo[3,2-c]quinoline-derivatives, compositions containing same, useful for treating pain, psychosis or convulsions |
JPH05502217A (ja) * | 1989-08-21 | 1993-04-22 | ベス イスラエル ホスピタル アソシエーション | セロトニン拮抗薬の局所用調製物を使用した、皮膚、眼、および粘膜の過敏症、炎症、および過増殖状態の治療のための方法および組成物 |
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
DK203990D0 (da) * | 1990-08-24 | 1990-08-24 | Novo Nordisk As | Piperazinylderivater |
US5605897A (en) | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
US5229832A (en) | 1991-07-08 | 1993-07-20 | Industrial Quality, Inc. | Optical ultrasonic material characterization apparatus and method |
US5321012A (en) * | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
CA2115792C (en) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
ES2236700T3 (es) * | 1993-11-19 | 2005-07-16 | Janssen Pharmaceutica N.V. | 1,2-benzazoles microencapsulados. |
KR970705390A (ko) * | 1994-09-02 | 1997-10-09 | 리차드 시 프란슨 | 비마약성 진통제(non-narcotic analgesic) 및 진통효과 향상제(analgesia enhancer)를 포함하는 통증 완화 조성물(COMPOSITION ALLEVIATING PAIN, CONTAINING A NON-NARCOTIC ANALGESIC AND AN ANALGESIA ENHANCER) |
JP3274579B2 (ja) * | 1995-01-12 | 2002-04-15 | 住友製薬株式会社 | 脳血管障害に伴う精神症候治療剤 |
GB9604465D0 (en) * | 1996-03-01 | 1996-05-01 | Smithkline Beecham Plc | Novel method |
WO1997035584A1 (en) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Method for treating pain |
IL126203A (en) | 1996-03-25 | 2002-12-01 | Lilly Co Eli | A synergistic painkiller that contains olenzapine and another painkiller |
-
1997
- 1997-03-24 WO PCT/US1997/004699 patent/WO1997035584A1/en active Application Filing
- 1997-03-24 AU AU25872/97A patent/AU2587297A/en not_active Abandoned
- 1997-03-24 JP JP9534520A patent/JP2000507544A/ja not_active Ceased
- 1997-03-24 EP EP97917594A patent/EP0906104A4/en not_active Withdrawn
- 1997-03-24 CA CA002250042A patent/CA2250042A1/en not_active Abandoned
-
2000
- 2000-02-04 US US09/498,047 patent/US6444665B1/en not_active Expired - Fee Related
-
2002
- 2002-08-15 US US10/224,224 patent/US6936601B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6936601B2 (en) | 2005-08-30 |
AU2587297A (en) | 1997-10-17 |
EP0906104A4 (en) | 2003-12-10 |
US20030013689A1 (en) | 2003-01-16 |
EP0906104A1 (en) | 1999-04-07 |
US6444665B1 (en) | 2002-09-03 |
CA2250042A1 (en) | 1997-10-02 |
WO1997035584A1 (en) | 1997-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000507544A (ja) | 痛みの治療方法 | |
US5945416A (en) | Method for treating pain | |
JP4977297B2 (ja) | トラマドール物質及び抗痙攣薬を含んで成る組成物 | |
TWI389689B (zh) | 氟利本西林(flibanserin)於治療停經前性慾疾病之用途 | |
JP2002529499A (ja) | 痛みの治療方法 | |
HU217833B (hu) | Eljárás difenil-butil-piperazin-karboxamidokat tartalmazó, mértéktelen szerfogyasztásból eredő betegségek kezelésére alkalmas gyógyszerkészítmények előállítására | |
BRPI0614792A2 (pt) | associação de um agente hipnótico com duração de ação longa e de um agente hipnótico com duração de ação curta e sua aplicação terapêutica | |
NZ538941A (en) | Pharmaceutical formulations of modafinil in solid dosage forms | |
BRPI0712360A2 (pt) | método para intensificação de função cognitiva | |
KR19990067698A (ko) | 세로토닌 재흡수 억제제의 위장 효과를 극복하기 위한 5ht4수용체 길항제의 용도 | |
JPH0635382B2 (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
EP1221950B1 (en) | Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog | |
CN110290788A (zh) | 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途 | |
US6511982B2 (en) | Treatment of pain | |
RU2258506C2 (ru) | Лекарственные средства для предупреждения и лечения нейродегенеративных заболеваний | |
HRP20010741A2 (en) | Use of osanetant in the production of medicaments used to treat mood disorders | |
JP2002503224A (ja) | 疼痛を処置するための組成物 | |
MX2010006520A (es) | Metodo y composicion para el tratamiento de una condicion mediada por alfa-adrenoceptor. | |
WO1998046601A1 (en) | Composition for treating pain | |
HRP980023A2 (en) | Use of beta3-adrenergic receptor antagonists for the preparation of healing drugs | |
US6566361B2 (en) | Azapirone pain treatment | |
AU1570200A (en) | Use of a 5HT2a and 5HT2a/c receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways | |
TW202010496A (zh) | 双那布扶林己二酸酯和乙醯胺酚的藥物製劑及治療疼痛的方法 | |
KR20000004965A (ko) | 통증 치료 방법 | |
MXPA01007833A (es) | Metodo para prevenir o reducir eventos cardiovasculares asociados con intervencion de la arteria coronaria. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040311 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040311 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071211 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080515 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080624 |